NCT02643264

Brief Summary

The purpose of this study is to investigate the effects of repetitive transcranial magnetic stimulation (rTMS) targeting the insula on alcohol use and neural responses in alcohol-dependent patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 21, 2015

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 31, 2015

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

December 31, 2015

Status Verified

December 1, 2015

Enrollment Period

2.1 years

First QC Date

December 21, 2015

Last Update Submit

December 28, 2015

Conditions

Keywords

insulaalcohol addictiontranscranial magnetic stimulation

Outcome Measures

Primary Outcomes (2)

  • Heavy Drinking

    Reduction in heavy alcohol use during the outpatient follow-up phase (%heavy drinking days) measured by standard Time-Line Follow-Back methodology

    12 weeks follow-up from treatment completion

  • Insula activity

    Insula activity (%signal change, as measured by fMRI BOLD), during a task known to be associated with insula responses, risky decision making

    Within 5 days of treatment completion

Secondary Outcomes (5)

  • BOLD responses in a battery of standard fMRI tasks that probe processing of alcohol-associated cues, reward function, and emotional responses.

    Within 5 days after the last TMS session

  • Alterations in resting-state connectivity of the insula with other nodes in the putative Salience Network (SN), executive control network (ECN) and the default-mode network (DMN) by rTMS.

    Within 5 days after the last TMS session

  • Objective biomarkers of alcohol use

    12 weeks follow-up from treatment completion

  • Alcohol craving and psychiatric symptoms

    12 weeks follow-up from treatment completion

  • Smoking

    12 weeks follow-up from treatment completion

Study Arms (2)

rTMS 10 Hz

EXPERIMENTAL

Deep Repetitive Transcranial Magnetic Stimulation (rTMS, 10 Hz) of the insula ,15 stimulation sessions (1 daily, 5 days / week).

Other: rTMS 10 Hz targeting the insula

rTMS Sham

SHAM COMPARATOR

Sham Repetitive Transcranial Magnetic Stimulation (rTMS, Sham),15 stimulation sessions (1 daily, 5 days / week).

Other: Sham rTMS

Interventions

Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session

rTMS 10 Hz

Sham stimulation with the same regimen as active treatment

rTMS Sham

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 - 65
  • Current Diagnostic and Statistical Manual (DSM-IV-TR) diagnosis of alcohol dependence
  • Alcohol use in the past month
  • Right handed (self-report)
  • If female, negative urine pregnancy test
  • If female, must either agree to practice an effective birth control method; have a partner with a vasectomy; agree to abstinence from intercourse; be surgically sterile or postmenopausal for at least one year

You may not qualify if:

  • Currently pregnant or breastfeeding
  • More than mild cognitive impairment, as determined by a score on the Mini Mental State Examination (MMSE) \<24.
  • Current DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychotic disorder
  • Use in the past 4 weeks of any medication or illicit drug listed as being associated with "a strong potential hazard for application of rTMS due to their significant seizure threshold lowering potential" by the international consensus guidelines for delivery of TMS \[104\], as self-reported, or detected using urine toxicology screening
  • Any history of clinically significant neurological disorders, including organic brain disease, epilepsy, stroke, brain lesions, multiple sclerosis, previous neurosurgery or personal history of head trauma that resulted in loss of consciousness for \> 5 minutes and retrograde amnesia for \> 30 minutes (self-reported history).
  • Any history of seizures other than febrile childhood seizures (self-reported history)
  • Signs of increased intracranial pressure as determined by the structural MRI-scan
  • Clinically significant hearing impairment or tinnitus
  • Presence of ferromagnetic objects in the body that are contraindicated for MRI of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments) or fear of enclosed spaces. Eligibility will be determined by the "MRI Safety Screening Questionnaire" (see Appendix 1) and verified, if necessary, by a radiology consultant.
  • Cannot recline comfortably flat on his/her back for up to 2 hours in the MRI scanner.
  • Any psychiatric, medical or social condition whether or not listed above, due to which, in the judgment of the investigators and after any consults if indicated, participation in the study is not in the best interest of the patient.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Linkoping University

Linköping, 581 85, Sweden

RECRUITING

MeSH Terms

Conditions

Alcoholism

Condition Hierarchy (Ancestors)

Alcohol-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Markus A Heilig, MD PhD

    Linkoeping University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Markus A Heilig, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 21, 2015

First Posted

December 31, 2015

Study Start

November 1, 2015

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

December 31, 2015

Record last verified: 2015-12

Data Sharing

IPD Sharing
Will share

Locations